logo

For the Inventor, By the Inventor

Petach-Tikva, Israel

Teva Pharmaceutical Industries Limited


USPTO Granted Patents = 505

% Expired Patents = 62.2



Trademarks = 30

Forward Citations = 4,287

Loading Chart...
Loading Chart...

501 inventors (with patents filed for the assignee):

goldMedal Judith Aronhime (68 out of 89 patents)

silverMedal Ben-Zion Dolitzky (44 out of 51 patents)

bronzeMedal Shlomit Wizel (32 out of 33 patents)

4.  Marioara Mendelovici (30 out of 30 patents)

5.  Tamar Nidam (28 out of 31 patents)

6.  Claude Singer (28 out of 36 patents)

7.  Nina Finkelstein (27 out of 27 patents)

8.  Revital Lifshitz-Liron (27 out of 27 patents)

9.  Valerie Niddam-Hildesheim (23 out of 27 patents)

10.  Vinod Kumar Kansal (22 out of 25 patents)

11.  Ruth Levy (21 out of 25 patents)

12.  Anita Liberman (20 out of 20 patents)

13.  Anton Frenkel (18 out of 21 patents)

14.  Jeffrey Sterling (18 out of 27 patents)

15.  Ramy Lidor-Hadas (18 out of 18 patents)


Core Competencies:
Glatiramer Acetate
Laquinimod
Injectable Devices
S1P3 Antagonists
Respiratory Apparatus
Biomarkers
Rasagiline
Formulations
Microparticles
Fingolimod
BDNF-related Disorders
Autoimmune Diseases

505 patents:

1. 12310929 - Use of rasagiline for the treatment of restless legs syndrome (2025-05-27),
2. 11938298 - Medical injection device packaging (2024-03-26),
3. 11642451 - Medical injection device packaging (2023-05-09),
4. 11472772 - S1P3 antagonists (2022-10-18),
5. D936824 - Injector pen (2021-11-23),
6. 11135154 - Medroxyprogesterone acetate injectable compositions and methods of use (2021-10-05),
7. 10232124 - Re-useable injector device for syringe (2019-03-19),
8. 10130621 - Analogs of pridopidine, their preparation and use (2018-11-20),
9. 10071206 - Re-useable injector device for syringe (2018-09-11),
10. D827127 - Injector pen (2018-08-28),
11. 9951017 - S1P3 antagonists (2018-04-24),
12. 9827374 - Re-useable injector device for syringe (2017-11-28),
13. 9763993 - Process for manufacturing glatiramer acetate product (2017-09-19),
14. 9702007 - Genetic markers predictive of response to glatiramer acetate (2017-07-11),
15. 9687522 - Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis (2017-06-27),
Company Overview
Teva Pharmaceutical Industries Limited is a global leader in the development and manufacturing of pharmaceutical compositions, with a strong focus on innovative therapies for various medical conditions. Headquartered in Petach-Tikva, Israel, the company specializes in a range of core technologies including Glatiramer Acetate, Laquinimod, and S1P3 antagonists, as well as advanced injectable devices and respiratory apparatus. Teva is committed to enhancing patient outcomes through its research in biomarkers and formulations, positioning itself as a key player in the pharmaceutical industry.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

Teva Pharmaceutical Industries Limited USPTO Patent Assignee Logo
505 Patents

#1 in Petach-Tikva

#12 in Israel

#1,921 in the World

Petach-Tikva, IL
Petach-Tikva, Israel

Teva Pharmaceutical Industries Limited

Forward Citations = 4,287

501 inventors:

goldMedal Judith Aronhime (68 out of 89 patents)

silverMedal Ben-Zion Dolitzky (44 out of 51 patents)

bronzeMedal Shlomit Wizel (32 out of 33 patents)

4.  Marioara Mendelovici (30 out of 30 patents)

5.  Tamar Nidam (28 out of 31 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Teva Pharmaceutical Industries Limited. Retrieved from https://idiyas.com/company/teva-pharmaceutical-industries

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…